BioVersys (BIOV) Stock Overview
Researches and develops antimicrobial drugs for bacterial infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
BIOV Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
BioVersys AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 27.00 |
| 52 Week High | CHF 33.60 |
| 52 Week Low | CHF 21.20 |
| Beta | 0 |
| 1 Month Change | 1.89% |
| 3 Month Change | 0.37% |
| 1 Year Change | -13.46% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -25.00% |
Recent News & Updates
Recent updates
BIOV: Higher Fair Value Will Support Stronger Long Term Profitability
Analysts have raised their price target for BioVersys from CHF 70 to CHF 100, citing updated assumptions for fair value, discount rate, revenue growth, profit margin and future P/E, which together support a higher valuation range. What’s in the News for BioVersys No recent news stories for BioVersys were identified in the provided sources as of 3 September 2026.
Antibiotic Subscription Reforms And External Funding Will Support Long Term Anti Infective Upside
Catalysts About BioVersys BioVersys develops antibiotics and anti infective therapies targeting high mortality, drug resistant infections and tuberculosis. What are the underlying business or industry changes driving this perspective?
Antibiotic Trial And Reimbursement Setbacks Will Pressure Results Before Long Term Potential Emerges
Catalysts About BioVersys BioVersys is a biopharmaceutical company focused on developing antibiotics for severe drug resistant infections and tuberculosis. What are the underlying business or industry changes driving this perspective?Global Antibiotic Partnerships And New Reimbursement Models Will Support Strong Future Potential
Catalysts About BioVersys BioVersys is a clinical stage biopharmaceutical company focused on antibiotics targeting severe drug resistant infections and tuberculosis. What are the underlying business or industry changes driving this perspective?Is BioVersys (VTX:BIOV) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Shareholder Returns
| BIOV | CH Pharmaceuticals | CH Market | |
|---|---|---|---|
| 7D | -3.6% | -5.8% | -2.8% |
| 1Y | -13.5% | 23.0% | 11.4% |
Return vs Industry: BIOV underperformed the Swiss Pharmaceuticals industry which returned 23% over the past year.
Return vs Market: BIOV underperformed the Swiss Market which returned 11.4% over the past year.
Price Volatility
| BIOV volatility | |
|---|---|
| BIOV Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 4.5% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 2.0% |
Stable Share Price: BIOV's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: BIOV's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 38 | Marc Gitzinger | www.bioversys.com |
BioVersys AG researches and develops antimicrobial drugs for bacterial infections. It develops BV100 that is in Phase 3 clinical trial for carbapenem-resistant Acinetobacter baumannii lung and bloodstream infections. The company is also developing Alpibectir, which is in Phase 2 clinical trial for the treatment of pulmonary and meningeal tuberculosis; BV200 to treat patients with Gram-positive S. aureus; and BV500 for non-tuberculous mycobacteria infections.
BioVersys AG Fundamentals Summary
| BIOV fundamental statistics | |
|---|---|
| Market cap | CHF 158.36m |
| Earnings (TTM) | -CHF 26.41m |
| Revenue (TTM) | CHF 4.62m |
Is BIOV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOV income statement (TTM) | |
|---|---|
| Revenue | CHF 4.62m |
| Cost of Revenue | CHF 0 |
| Gross Profit | CHF 4.62m |
| Other Expenses | CHF 31.03m |
| Earnings | -CHF 26.41m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.50 |
| Gross Margin | 100.00% |
| Net Profit Margin | -571.27% |
| Debt/Equity Ratio | 48.6% |
How did BIOV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/14 02:18 |
| End of Day Share Price | 2026/09/14 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioVersys AG is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jelena Milovic | Citigroup Inc |
| Jyoti Prakash | Edison Investment Research |
| Raghuram Selvaraju | H.C. Wainwright & Co. |